Key Highlights:
- Cipla and SBP Group’s subsidiary CTTQ have signed an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC. Cipla will develop and commercialize the therapy across India, South Africa and five emerging markets.
- TQB2102 is being evaluated across HER2-expressing cancers, with encouraging clinical potential in HER2-low advanced breast cancer. Its dual-epitope design targets two HER2 domains and combines a cleavable linker with a topoisomerase I inhibitor payload.
- Cipla will lead local clinical development, regulatory and commercialization activities, while CTTQ will manufacture and supply the ADC. The partnership aims to accelerate development and expand patient access across the licensed markets, subject to regulatory approvals.
Implications:
Cipla’s licensing deal adds a potential new HER2-targeted cancer treatment to its pipeline in India, South Africa and five other emerging markets, strengthening its ability to compete in the fast-growing market for advanced cancer medicines. The agreement lets Cipla use its local clinical, regulatory and commercial reach while CTTQ supplies the product, which could speed access to the therapy if it receives approvals and broaden treatment options for patients with HER2-expressing cancers, including HER2-low breast cancer.
Source: Cipla
